Related references
Note: Only part of the references are listed.Three Years of Continuous Entecavir Therapy in Treatment-Naive Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety
Man-Fung Yuen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis B
Nghiem B. Ha et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Entecavir Treatment for Chronic Hepatitis B: Adaptation Is Not Needed for the Majority of Naive Patients with a Partial Virological Response
Roeland Zoutendijk et al.
HEPATOLOGY (2011)
Virological Breakthrough and Resistance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogues in Clinical Practice
Chanunta Hongthanakorn et al.
HEPATOLOGY (2011)
Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice
E. Ridruejo et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update
Myron John Tong et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection
Tatyana A. Shamliyan et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2011)
Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection
Yun-Fan Liaw et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naive, Hepatitis B e Antigen-positive Patients Receiving Entecavir
Young Kul Jung et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2010)
Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion
George K. K. Lau
LIVER INTERNATIONAL (2010)
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen-Positive Patients with Chronic Hepatitis B: A Randomized International Study of Entecavir Versus Adefovir
Nancy Leung et al.
HEPATOLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: Phase II clinical study in Japan
Haruhiko Kobashi et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Ribavirin and IFN-α combination therapy induces CD4+T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B
Fen-Yu Ren et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China
Guangbi Yao et al.
HEPATOLOGY INTERNATIONAL (2007)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
TT Chang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
CL Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
D Lavanchy
JOURNAL OF VIRAL HEPATITIS (2004)
Hepatitis B e antigen and the risk of hepatocellular carcinoma
HI Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)